These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27560482)

  • 1. Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials.
    Zhang C; Yuan W; Fang J; Wang W; He P; Lei J; Wang C
    PLoS One; 2016; 11(8):e0161792. PubMed ID: 27560482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis.
    Elgebaly A; Radwan IA; AboElnas MM; Ibrahim HH; Eltoomy MF; Atta AA; Mesalam HA; Sayed AA; Othman AA
    J Gastrointestin Liver Dis; 2017 Mar; 26(1):59-67. PubMed ID: 28338115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
    PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol.
    Wicklow B; Wittmeier K; T' Jong GW; McGavock J; Robert M; Duhamel T; Dolinsky VW
    Biochem Cell Biol; 2015 Oct; 93(5):522-30. PubMed ID: 26305052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.
    Heebøll S; Kreuzfeldt M; Hamilton-Dutoit S; Kjær Poulsen M; Stødkilde-Jørgensen H; Møller HJ; Jessen N; Thorsen K; Kristina Hellberg Y; Bønløkke Pedersen S; Grønbæk H
    Scand J Gastroenterol; 2016; 51(4):456-64. PubMed ID: 26784973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease-A Meta-Analysis.
    Jakubczyk K; Skonieczna-Żydecka K; Kałduńska J; Stachowska E; Gutowska I; Janda K
    Nutrients; 2020 Aug; 12(8):. PubMed ID: 32823621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
    Chen S; Zhao X; Ran L; Wan J; Wang X; Qin Y; Shu F; Gao Y; Yuan L; Zhang Q; Mi M
    Dig Liver Dis; 2015 Mar; 47(3):226-32. PubMed ID: 25577300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol does not benefit patients with nonalcoholic fatty liver disease.
    Chachay VS; Macdonald GA; Martin JH; Whitehead JP; O'Moore-Sullivan TM; Lee P; Franklin M; Klein K; Taylor PJ; Ferguson M; Coombes JS; Thomas GP; Cowin GJ; Kirkpatrick CM; Prins JB; Hickman IJ
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2092-103.e1-6. PubMed ID: 24582567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Wei Z; Liu N; Tantai X; Xing X; Xiao C; Chen L; Wang J
    Hepatol Int; 2019 May; 13(3):302-313. PubMed ID: 30446932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Jalali M; Mahmoodi M; Mosallanezhad Z; Jalali R; Imanieh MH; Moosavian SP
    Complement Ther Med; 2020 Jan; 48():102283. PubMed ID: 31987259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Wei S; Yu X
    Complement Ther Med; 2021 Mar; 57():102635. PubMed ID: 33271299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose-response meta-analysis of randomized controlled trials.
    Baziar N; Parohan M
    Phytother Res; 2020 Mar; 34(3):464-474. PubMed ID: 31799714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials.
    Charytoniuk T; Drygalski K; Konstantynowicz-Nowicka K; Berk K; Chabowski A
    Nutrition; 2017 Feb; 34():108-117. PubMed ID: 28063505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D supplementation for nonalcoholic fatty liver disease in type 2 diabetes mellitus: A protocol for a systematic review and meta-analysis.
    Wang S; Cai B; Han X; Gao Y; Zhang X; Wang R; Zhang Y; Chen Q
    Medicine (Baltimore); 2020 May; 99(19):e20148. PubMed ID: 32384501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies.
    Zeng T; Zhang CL; Zhao XL; Xie KQ
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):646-53. PubMed ID: 24743504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Nigella sativa in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Tang G; Zhang L; Tao J; Wei Z
    Phytother Res; 2021 Aug; 35(8):4183-4193. PubMed ID: 33728708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of resveratrol supplementation in patients with type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease: an umbrella review of meta-analyses of randomized controlled trials.
    Zeraattalab-Motlagh S; Jayedi A; Shab-Bidar S
    Am J Clin Nutr; 2021 Nov; 114(5):1675-1685. PubMed ID: 34320173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.